Release Date: August 31, 2017
Expiration Date: August 31, 2018
Media: Internet - based
Community Practice Connections™: 1st Annual European Symposium on Lung Cancers™ features a summary of clinical evidence guiding best practices in the treatment of patients with non–small cell lung cancer (NSCLC), including recent developments with targeted agents and immunotherapy. Interactive clinical vignettes are followed by short video interviews with internationally renowned experts in the management of patients with NSCLC. The video interviews address decision points in the clinical vignettes and questions commonly faced in the community oncology practice setting by medical professionals engaged in the care of patients with NSCLC.
Acknowledgement of Commercial Support
This activity is supported by educational grants from Takeda Oncology, Genomic Health, and Novartis
CME/CE Activity Table of Contents
Module 1: Immunotherapy
Module 2: ALK
Module 3: EGFR
Module 4: BRAF
Instructions for This Activity and Receiving Credit
You will need to login to participate in the activity.
Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
At the end of the activity, “educational content/video files” will be available for your reference.
In order to receive a CME/CE certificate, participants must complete the activity.
Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.
This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, and other healthcare professionals involved in the treatment and management of patients with lung cancer. .
At the conclusion of this activity, you should be better prepared to:
Assess methods by which prognostic and predictive tumor characteristics can be identified in advanced forms of lung cancer
Utilize tumor and patient characteristics to optimize personalized treatment sequencing for patients with advanced NSCLC
Discuss current and emerging roles for single-agent and combination immunotherapeutic strategies in the management of advanced lung cancers
Apply personalized approaches to manage EGFR-mutated advanced NSCLC by assessment of mutation subtypes in multiple lines of care
Assess evolving data sets concerning the use of ALK inhibition in frontline and subsequent lines of care in advanced NSCLC
Discuss emerging targeted approaches for oncogenic drivers in NSCLC beyond EGFR and ALK
Identify approaches to address treatment-related toxicities in patients with lung cancer
Integrate personalized approaches to manage challenging cases in advanced lung cancer settings
Faculty, Staff, and Planners' Disclosures
Prof. Dr. med. Martin Reck
Head of the Thoracic Oncology and Clinical Trial Departments
Lung Clinic Grosshansdorf
Disclosure: Consultant/Advisory Boards: oche, Lilly, AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Novartis, Celgene; Speakers Bureau: Roche, Lilly, AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Novartis, Celgene.
Enriqueta Felip MD, PhD
Director Thoracic and Head and Neck Program
Department of Medical Oncology
Vall d'Hebron University Hospital
Disclosure: Consultant/Advisory Boards: Roche, Lilly, AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Novartis, Celgene; Speakers Bureau: Roche, Lilly, AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Novartis, Celgene.
Tony Mok, MD
Chairman, Dept. of Clinical Oncology
The Chinese University of Hong Kong
Hong Kong, China
Disclosure: Grant Research Support: AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ, Roche, Merck Sharp & Dohme, Clovis Oncology, Bristol-Myers Squibb, Eisai, Taiho; Consultant/Advisory Boards: AstraZeneca, Roche/Genentech, Pfizer, Lilly, Boehringer Ingelheim, Clovis Oncology, Merck Serono, Merck Sharp & Dohme, Novartis, SFJ, ACEA Boehringer Ingelheim Sciences, Vertex, Bristol-Myers Squibb, GeneDecode, OncoGenex, Celgene, Ignyta, Cirina; Shareholder: Sanomics Limited.
Solange Peters, MD-PhD, PD-MER
Head Medical Oncology
Chair Thoracic Malignancies
Lausanne University Hospital
Disclosure: No relevant financial relationships with commercial interests..
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
PER Pulses Recap™
PER Pulse Recap (1 of 3)
This first of 3 PER Pulse™ Recaps from the 1st Annual European Symposium on Lung Cancers™
focuses on recent developments for patients with oncogene-driven non–small cell lung cancer (NSCLC).
For patients with NSCLC and rearrangements in the anaplastic lymphoma kinase (ALK
) gene, data for 2 new first-line options were recently presented. In the phase III ASCEND-4 trial, patients were randomized to ceritinib or standard platinum-based chemotherapy. Ceritinib yielded superior progression-free survival (PFS) (16.6 months vs 8.1 months; hazard ratio [HR], 0.55; P
< .00001), leading to approval in the US in May 2017 and in Europe in June 2017. In the phase III global ALEX trial, PFS was superior with alectinib compared with crizotinib (12-month PFS, 68% vs 49%; HR, 0.47; P
< .001). The adverse event profile also favored alectinib, which was granted priority regulatory review in August 2017 in the US and was recommended for approval in October 2017 by the European Committee for Medicinal Products for Human Use. In patients with crizotinib-pretreated disease, brigatinib demonstrated a response rate of 54% and a median PFS of 12.9 months with step-up dosing (90 mg/day for 7 days, followed by 180 mg/day thereafter). These data led to approval in the US in April 2017 and submission to European authorities.
In patients with NSCLC and a BRAFV600E
mutation, the combination of dabrafenib and trametinib was granted approval in Europe in April 2017, followed by approval in the US in June 2017. This approval was based on results from a phase II trial with cohorts for newly diagnosed and platinum-pretreated patients. The primary endpoint of response rate was similar in both cohorts (64% and 63%, respectively).
PER Pulse Recap (2 of 3)
This second of 3 PER Pulse™ Recaps from the 1st Annual European Symposium on Lung Cancers™
focuses on recent phase III data on new therapies for patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR
The phase III FLAURA trial compared osimertinib with standard therapy (erlotinib or gefitinib), with a primary endpoint of progression-free survival (PFS) by investigator assessment. Median PFS was 18.9 months with osimertinib, compared with 10.2 months for standard therapy (hazard ratio [HR], 0.46; P
< .0001). These data led, in October 2017, to Breakthrough Therapy Designation from the US Food and Drug Administration for osimertinib as first-line therapy.
The phase III ARCHER 1050 study compared dacomitinib to gefitinib, although patients with brain or leptomeningeal metastases were not eligible for this trial. The median PFS was superior in the dacomitinib arm (14.7 months vs 9.2 months, HR, 0.59; P
< .0001). As of this writing, regulatory action for dacomitinib has not been announced.
PER Pulse Recap (3 of 3)
This third of 3 PER Pulse™ Recaps from the 1st Annual European Symposium on Lung Cancers™
focuses on the expansion of immunotherapy into stage III non–small cell lung cancer (NSCLC) and updates on immunotherapy in metastatic disease.
In the phase III PACIFIC trial, patients with unresectable stage III NSCLC who did not experience disease progression following concurrent chemoradiation therapy, were randomized to receive either durvalumab or placebo. Progression-free survival (PFS) and overall survival (OS) were the co-primary endpoints. Median PFS was superior in the durvalumab arm (16.8 months vs 5.6 months; hazard ratio [HR], 0.52; P
< .001); the trial continues to mature for the OS endpoint. Based on these data, durvalumab was filed with regulatory authorities in Europe in October 2017, and is a category 2A recommendation in the National Comprehensive Cancer Network guidelines in the US; Breakthrough Therapy Designation was also granted by the US Food and Drug Administration.
In the metastatic setting, the phase III KEYNOTE-024 trial established single-agent pembrolizumab as the first-line standard of care for patients with a PD-L1 expression level of ≥50%. In addition to superior PFS reported previously with pembrolizumab, updated results have shown median OS times for pembrolizumab versus chemotherapy (30.0 months vs 14.2 months; HR, 0.63; P
= .002). The phase II KEYNOTE-021 trial, which led to approval in the US for the combination of pembrolizumab with carboplatin/pemetrexed in patients with newly diagnosed nonsquamous NSCLC, continues to be updated. Data presented in September 2017 showed a median PFS of 19.0 months with the triplet, compared with 8.9 months with chemotherapy alone (HR, 0.54; P
= .0067). Finally, in patients with previously treated, metastatic NSCLC, atezolizumab was approved by the European Commission in September 2017.
For additional commentary about these topics and others, visit www.gotoper.com
to access more resources from the 1st Annual European Symposium on Lung Cancers™
, including downloadable slides from the meeting.